| Project/Area Number |
05670566
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Fukushima Medical College |
|---|
Principal Investigator |
YAMAMOTO Teiji Fukushima Medical College, Dept.Neurology, Professor, 医学部, 教授 (10106487)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAITO Tasuku Fukushima Medical College, Dept.Neurology, Instructor, 医学部, 助手 (20215544)
TSUKAMOTO Tetsuro Fukushima Medical College, Dept.Neurology, Associate Professor, 医学部, 助教授 (20171978)
|
|---|
| Project Period (FY) |
1993 – 1994
|
| Project Status |
Completed (Fiscal Year 1994)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1994: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1993: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | multiple sclerosis / anti-phospholipid antibodies / 2-glycoprotein I |
|---|
| Research Abstract |
We have measured serum antiphospholipid antibodies (aPL) in patients with multiple sclerosis (MS) using enzyme linked immunosorbent assey and examined the correlations between these antibodies and MS.This study included thirty-two patients with clinically definite MS,thirteen patients with other autoimmune neurological disease excluding collagen vascular diseases (disease control.A) , eight patients with collagen vascular diseases (disease control.B) and twenty-six healthy persons (normal control) . In MS group IgG antibody against cardiolipin (CL) was detected in 3 (9%) ; anti-CL antibody showed cofactor (2-glycoprotein I) dependency in 2 but one was cofactor independent. IgM antibody was elevated in 14 of 32 patients (449%) with MS,but cofactor dependency was not determined. However, this was significantly higer in frequecy than that of the disease control A (P<0.01) and normal control (P<0.01) . Each anti-CL IgG antibody purified from four patients had differed reactivities against DNA.In addition, the APLA positive group in MS possessed at higer rate of other autoantibodies such as antinuclear antibody than the negative group. However, clinically two groups of MS were indistinguishable. The higher incidence of APLA imply that a broad spectrum of autoantibodies might be produced in MS ; some antibodies presumably related directly to MS pathogenesis are yet to be identified but APLA might be one of those antibodies which are to be tested for the capability of central inflammation and demyelination.
|
